Enhanced SH3/Linker interaction overcomes Abl kinase activation by gatekeeper and myristic acid binding pocket mutations and increases sensitivity to small molecule inhibitors

Journal of Biological Chemistry

Volumn 288, Issue 9, 2013, Pages 6116-6129

  Panjarian, Shoghag ^a   Iacob, Roxana E ^b   Chen, Shugui ^b,c   Wales, Thomas E ^b   Engen, John R ^b   Smithgall, Thomas E ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE SITE; ALLOSTERIC CONTROL; BINDING POCKETS; BIOLOGICAL OBSERVATIONS; CHRONIC MYELOGENOUS LEUKEMIA; DRUG-TARGETING; DYNAMICS ANALYSIS; HYDROGEN EXCHANGE; KINASE ACTIVATION; KINASE ACTIVITY; KINASE DOMAINS; MULTI DOMAINS; MYRISTIC ACID; NETWORK LINKING; NON-CATALYTIC; SH2 DOMAIN; SMALL MOLECULE INHIBITOR; STRUCTURAL BASIS; TYROSINE KINASE;

AMINO ACIDS; CHEMICAL ACTIVATION; MASS SPECTROMETRY; MOLECULES; SATURATED FATTY ACIDS;

ENZYMES;

ABELSON KINASE; BCR ABL PROTEIN; IMATINIB; MYRISTIC ACID; PROTEIN SH2; PROTEIN SH3; SMALL MOLECULE TRANSPORT AGENT;

ALLOSTERISM; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; BINDING SITE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME STRUCTURE; GENE MUTATION; HUMAN; HUMAN CELL; HYDROGEN BOND; HYDROPHOBICITY; LIGAND BINDING; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION;

BINDING SITES; CELL LINE, TUMOR; ENZYME ACTIVATION; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MYRISTIC ACID; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-ABL; SRC HOMOLOGY DOMAINS;

EID: 84874326369     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.431312     Document Type: Article

References (38)

1. Wong, S., and Witte, O. N. (2004) The BCR-ABL story. Bench to bedside and back. Annu. Rev. Immunol. 22, 247-306
2. Hantschel, O., and Superti-Furga, G. (2004) Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat. Rev. Mol. Cell Biol. 5, 33-44
3. Druker, B. J. (2004) Imatinib as a paradigm of targeted therapies. Adv. Cancer Res. 91, 1-30
4. Nardi, V., Azam, M., and Daley, G. Q. (2004) Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr. Opin. Hematol. 11, 35-43
5. Griswold, I. J., MacPartlin, M., Bumm, T., Goss, V. L., O'Hare, T., Lee, K. A., Corbin, A. S., Stoffregen, E. P., Smith, C., Johnson, K., Moseson, E. M., Wood, L. J., Polakiewicz, R. D., Druker, B. J., and Deininger, M. W. (2006) Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol. Cell. Biol. 26, 6082-6093
6. Azam, M., Latek, R. R., and Daley, G. Q. (2003) Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCRABL. Cell 112, 831-843
7. Rix, U., Hantschel, O., Dürnberger, G., Remsing Rix, L. L., Planyavsky, M., Fernbach, N. V., Kaupe, I., Bennett, K. L., Valent, P., Colinge, J., Köcher, T., and Superti-Furga, G. (2007) Chemical proteomic profiles of the BCRABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110, 4055-4063
8. Nagar, B., Hantschel, O., Seeliger, M., Davies, J. M., Weis, W. I., Superti- Furga, G., and Kuriyan, J. (2006) Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. Mol. Cell 21, 787-798
9. Nagar, B., Hantschel, O., Young, M. A., Scheffzek, K., Veach, D., Bornmann, W., Clarkson, B., Superti-Furga, G., and Kuriyan, J. (2003) Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112, 859-871
10. Hantschel, O., Nagar, B., Guettler, S., Kretzschmar, J., Dorey, K., Kuriyan, J., and Superti-Furga, G. (2003) A myristoyl/phosphotyrosine switch regulates c-Abl. Cell 112, 845-857
11. Barilá, D., and Superti-Furga, G. (1998) An intramolecular SH3-domain interaction regulates c-Abl activity. Nat. Genet. 18, 280-282
12. Chen, S., O'Reilly, L. P., Smithgall, T. E., and Engen, J. R. (2008) Tyrosine phosphorylation in the SH3 domain disrupts negative regulatory interactions within the c-Abl kinase core. J. Mol. Biol. 383, 414-423
13. Meyn, M. A., 3rd, Wilson, M. B., Abdi, F. A., Fahey, N., Schiavone, A. P., Wu, J., Hochrein, J. M., Engen, J. R., and Smithgall, T. E. (2006) Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr- Abl transforming activity. J. Biol. Chem. 281, 30907-30916
14. Brasher, B. B., and Van Etten, R. A. (2000) c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J. Biol. Chem. 275, 35631-35637
15. Adrián, F. J., Ding, Q., Sim, T., Velentza, A., Sloan, C., Liu, Y., Zhang, G., Hur, W., Ding, S., Manley, P., Mestan, J., Fabbro, D., and Gray, N. S. (2006) Allosteric inhibitors of Bcr-Abl-dependent cell proliferation. Nat. Chem. Biol. 2, 95-102
16. Zhang, J., Adrián, F. J., Jahnke, W., Cowan-Jacob, S. W., Li, A. G., Iacob, R. E., Sim, T., Powers, J., Dierks, C., Sun, F., Guo, G. R., Ding, Q., Okram, B., Choi, Y., Wojciechowski, A., Deng, X., Liu, G., Fendrich, G., Strauss, A., Vajpai, N., Grzesiek, S., Tuntland, T., Liu, Y., Bursulaya, B., Azam, M., Manley, P. W., Engen, J. R., Daley, G. Q., Warmuth, M., and Gray, N. S. (2010) Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463, 501-506
17. Iacob, R. E., Zhang, J., Gray, N. S., and Engen, J. R. (2011) Allosteric interactions between the myristate- and ATP-site of the Abl kinase. PLoS One 6, e15929
18. McWhirter, J. R., Galasso, D. L., and Wang, J. Y. (1993) A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol. Cell. Biol. 13, 7587-7595
19. Pene-Dumitrescu, T., and Smithgall, T. E. (2010) Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner. J. Biol. Chem. 285, 21446-21457
20. Chen, S., Dumitrescu, T. P., Smithgall, T. E., and Engen, J. R. (2008) Abl N-terminal cap stabilization of SH3 domain dynamics. Biochemistry 47, 5795-5803
21. Iacob, R. E., Pene-Dumitrescu, T., Zhang, J., Gray, N. S., Smithgall, T. E., and Engen, J. R. (2009) Conformational disturbance in Abl kinase upon mutation and deregulation. Proc. Natl. Acad. Sci. U.S.A. 106, 1386-1391
22. Pene-Dumitrescu, T., Peterson, L. F., Donato, N. J., and Smithgall, T. E. (2008) An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259. Oncogene 27, 7055-7069
23. Wales, T. E., Fadgen, K. E., Gerhardt, G. C., and Engen, J. R. (2008) Highspeed and high-resolution UPLC separation at zero degrees Celsius. Anal. Chem. 80, 6815-6820
24. Wales, T. E., and Engen, J. R. (2006) Hydrogen exchange mass spectrometry for the analysis of protein dynamics. Mass Spectrom. Rev. 25, 158-170
25. Englander, S. W., and Kallenbach, N. R. (1983) Hydrogen exchange and structural dynamics of proteins and nucleic acids. Q. Rev. Biophys. 16, 521-655
26. Burkitt, W., and O'Connor, G. (2008) Assessment of the repeatability and reproducibility of hydrogen/deuterium exchange mass spectrometry measurements. Rapid Commun. Mass Spectrom. 22, 3893-3901
27. Plumb, R. S., Johnson, K. A., Rainville, P., Smith, B. W., Wilson, I. D., Castro-Perez, J. M., and Nicholson, J. K. (2006) UPLC/MS(E). A new approach for generating molecular fragment information for biomarker structure elucidation. Rapid Commun. Mass Spectrom. 20, 1989-1994
28. Seeliger, D., and de Groot, B. L. (2010) Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J. Comput. Aided Mol. Des. 24, 417-422
29. Pisabarro, M. T., Serrano, L., and Wilmanns, M. (1998) Crystal structure of the Abl-SH3 domain complexed with a designed high-affinity peptide ligand. Implications for SH3-ligand interactions. J. Mol. Biol. 281, 513-521
30. Yu, H., Chen, J. K., Feng, S., Dalgarno, D. C., Brauer, A. W., and Schreiber, S. L. (1994) Structural basis for the binding of proline-rich peptides to SH3 domains. Cell 76, 933-945
31. Feng, S., Chen, J. K., Yu, H., Simon, J. A., and Schreiber, S. L. (1994) Two binding orientations for peptides to the Src SH3 domain. Development of a general model for SH3-ligand interactions. Science 266, 1241-1247
32. Nagar, B., Bornmann, W. G., Pellicena, P., Schindler, T., Veach, D. R., Miller, W. T., Clarkson, B., and Kuriyan, J. (2002) Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62, 4236-4243
33. Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., and Kuriyan, J. (2000) Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289, 1938-1942
34. Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., and Sawyers, C. L. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880
35. Weis, D. D., Wales, T. E., Engen, J. R., Hotchko, M., and Ten Eyck, L. F. (2006) Identification and characterization of EX1 kinetics in H/D exchange mass spectrometry by peak width analysis. J. Am. Soc. Mass Spectrom. 17, 1498-1509
36. Filippakopoulos, P., Kofler, M., Hantschel, O., Gish, G. D., Grebien, F., Salah, E., Neudecker, P., Kay, L. E., Turk, B. E., Superti-Furga, G., Pawson, T., and Knapp, S. (2008) Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation. Cell 134, 793-803
37. Kitamura, T., Tange, T., Terasawa, T., Chiba, S., Kuwaki, T., Miyagawa, K., Piao, Y.-F., Miyazono, K., Urabe, A., and Takaku, F. (1989) Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J. Cell. Physiol. 140, 323-334
38. Engen, J. R., Wales, T. E., Hochrein, J. M., Meyn, M. A., 3rd, Banu Ozkan, S., Bahar, I., and Smithgall, T. E. (2008) Structure and dynamic regulation of Src-family kinases. Cell Mol. Life Sci. 65, 3058-3073